Research programme: sickle cell anaemia therapy - Virginia Commonwealth University/Xechem

Drug Profile

Research programme: sickle cell anaemia therapy - Virginia Commonwealth University/Xechem

Alternative Names: 5-HMF

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Virginia Commonwealth University
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia

Highest Development Phases

  • No development reported Sickle cell anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA (PO)
  • 08 Jun 2006 5-HMF has received orphan drug status for sickle cell disease in the US
  • 13 Dec 2005 Preclinical trials in Sickle cell anaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top